Also known as: Verzenio
Abemaciclib is an oral selective CDK4/6 inhibitor used in hormone receptor-positive, HER2-negative breast cancer across metastatic and certain early-stage settings.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.
CDK4/6 inhibitors have transformed HR+/HER2− breast cancer treatment, while emerging resistance mechanisms are driving development of selective CDK2 inhibitors and dual CDK2/4 strategies to address treatment failure.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07492641 |
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease |
RECRUITING | PHASE3 |
| NCT07487129 |
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt |
COMPLETED | PHASE4 |
| NCT07441369 |
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07428018 |
Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib |
NOT_YET_RECRUITING | PHASE2 |
| NCT07209449 |
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer |
RECRUITING | PHASE2 |
| NCT07191717 |
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial |
NOT_YET_RECRUITING | PHASE2 |
| NCT07174336 |
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) |
RECRUITING | PHASE3 |
| NCT07112053 |
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer |
RECRUITING | PHASE2 |
| NCT07100106 |
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT06835972 |
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) |
RECRUITING | PHASE1/PHASE2 |
